| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.9 | -2.8 |
| Net income | -2.9 | -2.8 |
| EPS (diluted, $ a share) | $-0.29 | $-6.71 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: AZTR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Azitra, Inc.: key numbers
- Share price
- $0.6270Close, Nov 16
- Market cap
- $3.8M
- Shares outstanding
- 6.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Azitra, Inc.
All →Azitra Financial Results
Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.
- Term
- Q3 2026
“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”
Francisco Salva, Chief Executive Officer
“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”
Francisco Salva, Chief Executive Officer
Azitra Clinical Trial Data
Azitra announced positive ex vivo human skin model data for its ATR-COSF program, showing a 56% reduction in wrinkles and improved skin elasticity. The company plans to initiate a first-in-human study for the filaggrin-based topical cosmetic with initial results expected by year-end 2026. Additionally, the company provided updates on its ATR-04 Phase 1/2 trial, which has been expanded to include patients with rashes from KRAS and MEK inhibitors.
Azitra Business Update
Azitra has amended its Phase 1/2 clinical trial protocol for ATR-04 to expand patient eligibility to include those with rashes caused by KRAS and MEK inhibitors, as well as NF1 patients. The company also shortened required washout periods for antibiotics and steroids to accelerate patient recruitment and enrollment for Cohort 2 of the study.
Azitra Deal Termination with A.G.P./Alliance Global Partners
Azitra, Inc. announced it has decided to suspend and not utilize its at-the-market (ATM) offering program with A.G.P./Alliance Global Partners for the foreseeable future. The company cited its current capital resources, upcoming milestones, and the dilutive effect of equity issuances as reasons for the decision. Separately, the company released positive ex vivo study data for its ATR-COSF cosmetic program showing improvements in skin elasticity and fine lines.
- Counterparty
- A.G.P./Alliance Global Partners
Azitra Reverse Stock Split
Azitra, Inc. has filed a certificate of amendment to effectuate a 1-for-10 reverse stock split of its common stock, effective October 26, 2026. The split aims to consolidate every 10 shares into one share to adjust the trading price on the NYSE American. No fractional shares will be issued, with stockholders receiving cash payments in lieu of fractional interests.
Azitra Clinical Trial Data
Azitra, Inc. has completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate for treating skin rash associated with EGFR inhibitors. Following a safety review committee clearance, the company is proceeding to enroll approximately 24 patients in Cohort 2 to further evaluate safety, tolerability, and preliminary efficacy.